The insulinotropic effect of 50 g galactose given orally to 5 normal volunteers on two occasions -once with and once without a period of hyperglycaemia produced by an intravenous glucose infusion -was studied. Oral galactose caused a rise in plasma GIP from fasting levels of 260 • 50 ng/1 (mean • S. E. M.) to a maximum of 900 • 65 ng/1 30 min after ingestion, but in the presence of induced hyperglycaemia the GIP response was significantly diminished and delayed (maximum plasma GIP levels 595 • 110 ng/1 at 45 rain, p < 0.05). The insulin response to galactose was greatly enhanced by IV glucose (mean area under plasma insulin curve with galactose alone 236.5 • 66.0, with galactose + IV glucose 451.9 _+ 81.6, p < 0.025). The mean rise in plasma galactose was significantly lower in the presence of IV glucose (mean peak level 1.97 _-2 0.28 mmol/1 with galactose alone, 0.69 • 0.16 mmol/l galactose + IV glucose, p < 0.025). Oral galactose caused the release of GIP, which is powerfully insulinotropic in the presence of moderate hyperglycaemia. The lower plasma GIP and galactose levels observed following oral galactose in the presence of IV glucose may be accounted for either by postulating that insulin inhibits the absorption of oral galactose, or that insulin exerts a negative feed-back control on GIP release and accelerates gatactose disposition in the body.
Glucose stimulates insulin secretion by direct action on the B-cell as well as by the liberation of intestinal insulin releasing hormones. Galactose, on the other hand, though capable of stimulating insulin secretion when taken orally [8] fails to do so when administered intravenously [6, 8] . This suggests that the insulin stimulatory effect of oral galactose is mediated largely, if not entirely, through its capacity to release one or more of the intestinal insulin-releasing hormones. At present, GIP is the major contender for the role of intestinal mediator of insulin release [3] .
We have therefore investigated the insulin and GIP stimulatory properties of galactose in a group of normal healthy volunteers on two occasions; once after the ingestion of galactose alone and once after the ingestion of galactose during the course of an intravenous infusion of glucose.
Materials and Methods
Five healthy volunteers drawn from amongst the laboratory staff participated in the experiments. Three were men and two were women and their ages ranged between 25 and 35 years. All were within 10% of ideal body weight and had been eating a normal diet containing not less than 200 g carbohydrate per day until the evening preceding the tests. None of the volunteers were taking any drugs at the time of study.
Each subject attended the laboratory on two occasions having fasted since 2000 h the previous evening. A plastic cannula was inserted into an antecubital vein and kept patent with sodium citrate solution (130 mM) to facilitate sample collection. On one of the two occasions a butterfly needle was inserted into an antecubital vein in the opposite arm through which a bolus injection of glucose (25 ml of 50 g/100 ml) was given followed immediately by a constant intravenous infusion of 10 g/100 ml glucose at a rate of 0.25 g/kg/h for three hours. On both occasions at 1000 h, one hour after the experiment had begun, the subjects drank 50 g galactose dissolved in 300 ml of chilled water flavoured with lemon juice (final pH 4.0). Blood was collected at frequent intervals before and during the course of the experiments. Some was preserved in fluoride for later analysis for glucose content by an automated glucose oxidase technique [11] . Some of the blood was put into a lithium heparin tube, the plasma separated immediately and used for galactose analysis by a galactose dehydrogenase technique ple was put into lithium heparin tubes containing sufficient aprotinin to produce a final concentration of 500 k. i. units/ml blood. The mixture was centrifuged immediately, the plasma separated, frozen and stored at -20 ~ until assayed for immunoreactive insulin [14] and GIP [10] . Measurement of GIP was by radioimmunoassay using a rabbit antiserum raised against porcine GIP, using porcine G1P standards. The assay was able to distinguish 70-110 pg/ml GIP from zero in plasma samples. The antiserum showed less than 1% cross reactivity with glucagon, GIP, secretin, pancreatic polypeptide, insulin or C-peptide. Preliminary work indicates that the antiserum can recognise big GIP (MW 8,000 Daltons) and standard GIP (MW 5,300 Daitons). (O'Dorisio, T., Personal communication).
The "galactose-only" tests were carried out first; the infusion experiments later. The subjects sat comfortably, at ease, in the investigation unit throughout their performance. None of the subjects experienced abdominal or other discomfort at any time during the tests. The results were compared using Student's paired-t test. Informed consent was obtained from all subjects, and permission to carry out the experiments was obtained from St. Luke's Hospital ethical committee. 
Results
The results of the two series of experiments are summarised and compared in Figures 1-4 .
Oral Galactose Alone
The ingestion of galactose was followed in every case (Fig. 1) by a large and rapid rise in plasma GIP (mean peak level 900 _+ 65 ng/1 at 30 min) and a small (Fig. 2 ) rise in plasma insulin levels. Plasma galactose levels rose slowly at first, reaching a peak (mean peak level 1.97 _+ 0.28 mmol/1) at 60 min and had returned almost to basal values by 120min (Fig. 3) . Blood glucose showed a small but significant rise during the first 45 min following the ingestion of galactose (Fig. 4) but had returned to baseline values, or below, by 90 min.
Intravenous Glucose Plus Oral Galactose
Bolus injection, followed by continuous infusion of glucose, produced a rapid rise both in blood glucose and plasma insulin levels (Figs. 2 & 4) . Blood glucose levels reached a peak within five minutes of the bolus injection and fell slowly thereafter despite constant intravenous infusion of glucose at the rate of 0.25 g/ kg/h (Fig. 4) . Plasma insulin levels rose rapidly initially (Fig. 2) but fell almost equally rapidly to a new supra-basal plateau. Thereafter, plasma insulin levels remained more or less constant until the ingestion of oral galactose when they rose once again, this time to a level considerably higher than after galactose alone (53.3 _+ 10.7 mU/1 v. 20.5 + 2.8 mU/1). Comparison of the total area under the plasma insulin curve following the administration of oral galactose (from 60-180min) showed a significantly greater insulinaemic response to galactose given during the IV glucose infusion than when galactose was given alone. (Area under curve with galactose alone, 236.5 + 66.0, with galactose + IV glucose 451.9 _+ 81.6, p < 0.025 estimated using the 60 min plasma insulin level as a baseline). Plasma GIP levels declined slowly and significantly throughout the period of intravenous glucose infusion until interrupted by the ingestion of galactose (GIP levels between 10 and 60 min being significantly lower (p < 0.05) than plasma GIP at zero time). Thereafter, plasma GIP levels rose (mean peak level 595 _+ 110 ng/1 at 45 minutes) though more slowly and to a significantly lesser extent than after oral galactose alone. Plasma galactose levels (Fig. 3) showed a consistently smaller rise (p < 0.025) than when galactose was ingested in the absence of an intravenous glucose infusion.
Discussion
The work reported here indicates that, in man, galactose ingestion, like that of glucose [3] is associated with a large brisk rise in plasma GIP concentrations. Reports of the GIP releasing properties of galactose are conflicting. Of the three abstracts relating to GIP release in dogs after oral galactose, two report a rise in plasma GIP levels -albeit a rather small one -and one no significant change [9, 16, 18] . One recent communication [13] relating to man reports a small rise in plasma GIP levels after oral galactose.
GIP is relatively ineffective in stimulating insulin release except in the presence of mild to moderate hyperglycaemia [3] . This may account for some of the reported failures to observe a rise in plasma insulin levels following oral galactose administration [1] .
Since the insulinotropic effect of GIP is enhanced by hyperglycaemia we decided to compare the GIP releasing and insulinotropic effects of oral galactose in the presence and absence of induced hyperglycaemia. It did not prove possible, as had been intended, to maintain a constant blood glucose concentration throughout the period of induced hyperglycaemia. Nevertheless, even in the presence of a declining blood glucose concentration the administration of 50g galactose by mouth was promptly followed by a large rise in plasma insulin concentration.
A small rise in blood glucose concentration is commonly, though not invariably, observed during the first hour following ingestion of galactose as in the present series of experiments. We suggest that this small rise in blood glucose concentration makes the B-cells of the pancreas receptive to the rise in plasma GIP levels produced by oral galactose and indirectly responsible, therefore, for the modest rise in plasma insulin concentration observed when galactose is ingested alone [8, 15] . The much larger rise in plasma insulin provoked by the ingestion of galactose in the artificially induced hyperglycaemic subjects was associated with a significantly smaller and delayed rise in plasma GIP concentration. The reduction in plasma GIP response to oral galactose under these circumstances could be accounted for by operation of a negative feedback control of GIP secretion by insulin [3] . It could, however, be due to inhibition of galactose absorption. The much lower plasma galactose level observed when the subjects drank their galactose solution whilst receiving IV glucose compared with when they drank it alone, was unexpected. Addition of glucose into the gut has been reported to interfere with active jejunal galactose transport to different degrees in various species [5, 12] . It appears unlikely that IV glucose could act in this way, although the possibility must be considered that hyperglycaemia in some way delays gastric emptying -possibly by inhibition of motilin secretion (Bloom, S. R., personal communication). Beyreiss and co-workers [2] reported the inhibition of galactose absorption from the gut in rabbits by the infusion of exogenous insulin. The higher endogenous insulin levels attained when our human subjects received IV glucose could therefore interfere with their galactose absorption. Another explanation of the lower rise in plasma galactose levels when subjects were receiving IV glucose is that whilst galactose absorption is unchanged by this manoeuvre, its clearance from the plasma is increased as a result of the greater hyperinsulinaemia. Most cells of the body -with the notable exception of those in the liver -are virtually impermeable to glucose and galactose, except in the presence of insulin [4, 7, 17] . Oral galactose alone is a poor stimulus to insulin secretion and consequently galactose is excluded from entry into all but liver cells. However, the higher insulin levels attained when subjects received IV glucose could render peripheral tissues more permeable to galactose. Animal experiments have shown that exogenous insulin increases galactose removed from the blood and its entry into peripheral tissues [6, 7, 17] where it is probably metabolised by a pathway not involving the enzyme galactokinase.
The role of insulin is regulating the metabolism of galactose has largely been ignored in the past, probably because, under most experimental conditions it does not stimulate insulin secretion -or does so to only a slight extent. Under most natural conditions of usage, however, namely when consumed as lactose, galactose can and does stimulate insulin secretion which could then proceed to play a part in its metabolism.
